Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 8/2014

01-08-2014 | Short Communication

Why Dried Blood Spots Are an Ideal Tool for CYP1A2 Phenotyping

Authors: Pieter M. M. De Kesel, Willy E. Lambert, Christophe P. Stove

Published in: Clinical Pharmacokinetics | Issue 8/2014

Login to get access

Abstract

Background and Objective

Dried blood spot (DBS) sampling has gained wide interest in bioanalysis during the last decade and has already been successfully applied in pharmacokinetic and phenotyping studies. However, all of the available phenotyping studies used small datasets and did not include a systematic evaluation of DBS-specific parameters. The latter is important since several of these factors still challenge the breakthrough of DBS in routine practice. In this study, caffeine and paraxanthine are determined in capillary DBS, venous DBS, whole blood and plasma for cytochrome P450 (CYP) 1A2 phenotyping. The aim of this study was to explore the usefulness of DBS as a tool for CYP1A2 phenotyping.

Methods

A CYP1A2 phenotyping study was conducted in 73 healthy volunteers who received a 150 mg oral dose of caffeine. Six hours post-administration, caffeine and paraxanthine concentrations and paraxanthine:caffeine molar concentration ratios, i.e., the actual CYP1A2 phenotyping indices, were determined in capillary DBS (obtained by non-volumetric application, direct from the fingertip), venous DBS, whole blood, and plasma. Furthermore, the impact of DBS-specific parameters, including hematocrit, volume spotted, and punch location, was evaluated.

Results

Concentrations of caffeine and paraxanthine in capillary DBS were, respectively, on average 12.7 and 13.8 % lower than those in venous DBS and 31.5 and 33.1 % lower than those in plasma. While these differences were statistically significant (p < 0.001), no significant difference was observed between the paraxanthine:caffeine molar ratios in the distinct evaluated matrices (p ≥ 0.053). This ratio also alleviated the impact of hematocrit and volume spotted.

Conclusions

Using the largest DBS-based phenotyping study to date, we have demonstrated that CYP1A2 phenotyping in capillary DBS is a valid and convenient alternative for the classical plasma-based approach. Additionally, we have provided an objective basis as to why DBS are an ideal tool for CYP1A2 phenotyping.
Appendix
Available only for authorised users
Literature
1.
2.
Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31(3):327–36.PubMedCrossRef
3.
Li W, Tse FL. Dried blood spot sampling in combination with LC–MS/MS for quantitative analysis of small molecules. Biomed Chromatogr. 2010;24(1):49–65.PubMedCrossRef
4.
Meesters RJ, Hooff GP. State-of-the-art dried blood spot analysis: an overview of recent advances and future trends. Bioanalysis. 2013;5(17):2187–208.PubMedCrossRef
5.
Stove CP, Ingels AS, De Kesel PM, Lambert WE. Dried blood spots in toxicology: from the cradle to the grave? Crit Rev Toxicol. 2012;42(3):230–43.PubMedCrossRef
6.
Ingels AS, Hertegonne K, Lambert WE, Stove CP. Feasibility of following up gamma-hydroxybutyric acid concentrations in sodium oxybate (Xyrem®)-treated narcoleptic patients using dried blood spot sampling at home: an exploratory study. CNS Drugs. 2013;27(3):233–7.PubMedCrossRef
7.
Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGready R, et al. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2010;66(7):705–12.PubMedCentralPubMedCrossRef
8.
Mohammed BS, Cameron GA, Cameron L, Hawksworth GH, Helms PJ, Mclay JS. Can finger-prick sampling replace venous sampling to determine the pharmacokinetic profile of oral paracetamol? Brit J Clin Pharmacol. 2010;70(1):52–6.CrossRef
9.
10.
De Kesel PM, Sadones N, Capiau S, Lambert WE, Stove CP. Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis. 2013;5(16):2023–41.PubMedCrossRef
11.
Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis. 2010;2(8):1385–95.PubMedCrossRef
12.
O’Mara M, Hudson-Curtis B, Olson K, Yueh Y, Dunn J, Spooner N. The effect of hematocrit and punch location on assay bias during quantitative bioanalysis of dried blood spot samples. Bioanalysis. 2011;3(20):2335–47.PubMedCrossRef
13.
Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry. 2007;12(8):707–47.PubMedCrossRef
14.
Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84(1):52–62.PubMedCrossRef
15.
Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics. 1999;9(2):131–44.PubMed
16.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.PubMedCrossRef
17.
Kalow W, Tang BK. The use of caffeine for enzyme assays—a critical appraisal. Clin Pharmacol Ther. 1993;53(5):503–14.PubMedCrossRef
18.
Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther. 2007;81(2):270–83.PubMedCrossRef
19.
Perera V, Gross AS, McLachlan AJ. Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr Drug Metab. 2012;13(5):667–78.PubMedCrossRef
20.
de Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I, et al. Application of dried blood spot sampling combined with LC–MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr. 2011;25(10):1112–23.PubMedCrossRef
21.
Daali Y, Samer C, Deglon J, Thomas A, Chabert J, Rebsamen M, et al. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther. 2012;91(3):489–96.PubMedCrossRef
22.
Bosilkovska M, Deglon J, Samer C, Walder B, Desmeules J, Staub C, et al. Simultaneous LC–MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis. 2014;6(2):151–64.PubMedCrossRef
23.
Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Krahenbuhl S, et al. The Basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet. 2014;53(3):271–82.PubMedCrossRef
24.
De Kesel PM, Lambert WE, Stove CP. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma. Bioanalysis. In Press.
25.
26.
27.
Capiau S, Stove VV, Lambert WE, Stove CP. Prediction of the hematocrit of dried blood spots via potassium measurement on a routine clinical chemistry analyzer. Anal Chem. 2013;85(1):404–10.PubMedCrossRef
28.
Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011;63(9):1161–8.PubMedCrossRef
29.
Dewitte K, Fierens C, Stockl D, Thienpont LM. Application of the Bland–Altman plot for interpretation of method-comparison studies: a critical investigation of its practice. Clin Chem. 2002;48(5):799–801.PubMed
30.
Rainey PM. Relation between serum and whole-blood ethanol concentrations. Clin Chem. 1993;39(11):2288–92.PubMed
31.
Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II). Clin Pharmacokinet. 1989;17(4):275–90.PubMedCrossRef
32.
Holub M, Tuschl K, Ratschmann R, Strnadova KA, Muhl A, Heinze G, et al. Influence of hematocrit and localisation of punch in dried blood spots on levels of amino acids and acylcarnitines measured by tandem mass spectrometry. Clin Chim Acta. 2006;373(1–2):27–31.PubMedCrossRef
33.
Ingels AS, De Paepe P, Anseeuw K, Van Sassenbroeck D, Neels H, Lambert W, et al. Dried blood spot punches for confirmation of suspected gamma-hydroxybutyric acid intoxications: validation of an optimized GC–MS procedure. Bioanalysis. 2011;3(20):2271–81.PubMedCrossRef
34.
Mess JN, Taillon MP, Cote C, Garofolo F. Dried blood spot on-card derivatization: an alternative form of sample handling to overcome the instability of thiorphan in biological matrix. Biomed Chromatogr. 2012;26(12):1617–24.PubMedCrossRef
35.
Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(15–16):1063–70.PubMedCrossRef
36.
Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther. 2011;90(1):117–25.PubMedCrossRef
37.
Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics. 2001;11(5):429–35.PubMedCrossRef
Metadata
Title
Why Dried Blood Spots Are an Ideal Tool for CYP1A2 Phenotyping
Authors
Pieter M. M. De Kesel
Willy E. Lambert
Christophe P. Stove
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2014
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-014-0150-5

Other articles of this Issue 8/2014

Clinical Pharmacokinetics 8/2014 Go to the issue

Review Article

Clinical Pharmacology of Deferasirox

Review Article

A Comprehensive Review on the Pharmacokinetics of Antibiotics in Interstitial Fluid Spaces in Humans: Implications on Dosing and Clinical Pharmacokinetic Monitoring

Original Research Article

Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥40 kg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring

Original Research Article

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

Original Research Article

Pharmacokinetics of Orally Administered Duloxetine in Children and Adolescents with Major Depressive Disorder

Current Opinion

Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved